Avalet 20 mg Medicine Services
Posted: Wed Jan 29, 2025 6:40 am
Avalet 20 mg, containing the active ingredient Avatrombopag, is a thrombopoietin receptor agonist used primarily to treat thrombocytopenia (low blood platelet count) in individuals with chronic liver disease undergoing medical procedures or in patients with chronic immune thrombocytopenia (ITP). Avatrombopag works by stimulating platelet production, helping to prevent excessive bleeding during medical treatments or due to an underlying condition.
Composition and Formulation
Avalet 20 mg contains:
Active Ingredient: Avatrombopag maleate, equivalent to 20 mg of Avatrombopag.
Excipients: Microcrystalline cellulose, mannitol, magnesium stearate, colloidal silicon dioxide, and other inactive ingredients that aid in tablet stability and absorption.
Dosage Form: Avalet 20 mg (Avatrombopag) is available as an oral tablet for convenient administration.
Mechanism of Action
Avatrombopag is a non-peptide thrombopoietin receptor agonist that selectively binds to and activates the thrombopoietin receptor (TPO-R or c-Mpl) found on hematopoietic stem cells and megakaryocytes in the bone marrow. This stimulation enhances the proliferation and differentiation of these cells into mature platelets, thereby increasing platelet production in circulation without directly stimulating cytokine release.
Indications and Usage
Avalet 20 mg is prescribed for:
Chronic Liver Disease (CLD)-Related Thrombocytopenia: To increase platelet counts in adult patients with chronic liver disease who are scheduled for medical or dental procedures.
Chronic Immune Thrombocytopenia (ITP): Used in adult patients with chronic ITP who have had an insufficient response to previous treatments such as corticosteroids, immunoglobulins, or splenectomy.
Dosage and Administration
For Chronic Liver Disease (CLD):
Recommended dose: 40 mg (two 20 mg tablets) once daily for five consecutive days before a scheduled procedure.
For Chronic Immune Thrombocytopenia (ITP):
The starting dose is usually 20 mg once daily, with dosage adjustments based on platelet response.
The treatment duration varies based on clinical response, with periodic monitoring of platelet levels.
Avalet 20 mg should be taken with food for optimal absorption.
Contraindications
Known hypersensitivity to Avatrombopag or any excipients in Avalet 20 mg.
Patients with a history of thrombosis (blood clot formation) should use caution, as Avatrombopag may increase the risk of clotting events.
Warnings and Precautions
Thrombotic Risk: Patients receiving Avatrombopag should be monitored for signs of excessive platelet production, which can increase the risk of thrombosis.
Hepatic Impairment: Caution is advised in patients with severe liver disease as dosage adjustments may be required.
Bleeding Risk: While Avatrombopag increases platelet count, it does not treat underlying causes of bleeding disorders; additional treatment may be necessary.
Pregnancy and Lactation: Use in pregnant or breastfeeding women should be considered only if the potential benefit justifies the risk.
Side Effects
Common adverse reactions associated with Avalet 20 mg include:
Headache
Fatigue
Nausea
Fever
Abdominal pain
Edema (swelling)
Insomnia
Thrombosis in rare cases
Serious side effects, though uncommon, may include blood clot formation, severe allergic reactions, or liver function abnormalities. Immediate medical attention is required if symptoms such as chest pain, shortness of breath, or unusual bruising occur.
Drug Interactions
Strong CYP3A4 inhibitors or inducers may alter the metabolism of Avatrombopag, requiring dose adjustments.
Anticoagulants and Antiplatelet Drugs: Concomitant use with blood thinners may require monitoring to balance the risk of clotting versus bleeding.
Iron Supplements: Iron and certain other minerals may affect Avatrombopag absorption; take them at least 4 hours apart.
Storage and Handling
Store at room temperature (15–30°C) away from direct sunlight and moisture.
Keep out of reach of children.
Do not use beyond the expiration date indicated on the packaging.
Conclusion
Avalet 20 mg (Avatrombopag) is an effective thrombopoietin receptor agonist that helps increase platelet counts in patients with chronic liver disease or chronic immune thrombocytopenia. It provides an oral, convenient alternative to platelet transfusions or other treatments, reducing the risk of bleeding complications in at-risk patients. However, careful monitoring and adherence to dosage guidelines are essential to ensure safety and efficacy. Patients should consult their healthcare provider for personalized treatment plans and regular follow-ups while on Avalet therapy.
Composition and Formulation
Avalet 20 mg contains:
Active Ingredient: Avatrombopag maleate, equivalent to 20 mg of Avatrombopag.
Excipients: Microcrystalline cellulose, mannitol, magnesium stearate, colloidal silicon dioxide, and other inactive ingredients that aid in tablet stability and absorption.
Dosage Form: Avalet 20 mg (Avatrombopag) is available as an oral tablet for convenient administration.
Mechanism of Action
Avatrombopag is a non-peptide thrombopoietin receptor agonist that selectively binds to and activates the thrombopoietin receptor (TPO-R or c-Mpl) found on hematopoietic stem cells and megakaryocytes in the bone marrow. This stimulation enhances the proliferation and differentiation of these cells into mature platelets, thereby increasing platelet production in circulation without directly stimulating cytokine release.
Indications and Usage
Avalet 20 mg is prescribed for:
Chronic Liver Disease (CLD)-Related Thrombocytopenia: To increase platelet counts in adult patients with chronic liver disease who are scheduled for medical or dental procedures.
Chronic Immune Thrombocytopenia (ITP): Used in adult patients with chronic ITP who have had an insufficient response to previous treatments such as corticosteroids, immunoglobulins, or splenectomy.
Dosage and Administration
For Chronic Liver Disease (CLD):
Recommended dose: 40 mg (two 20 mg tablets) once daily for five consecutive days before a scheduled procedure.
For Chronic Immune Thrombocytopenia (ITP):
The starting dose is usually 20 mg once daily, with dosage adjustments based on platelet response.
The treatment duration varies based on clinical response, with periodic monitoring of platelet levels.
Avalet 20 mg should be taken with food for optimal absorption.
Contraindications
Known hypersensitivity to Avatrombopag or any excipients in Avalet 20 mg.
Patients with a history of thrombosis (blood clot formation) should use caution, as Avatrombopag may increase the risk of clotting events.
Warnings and Precautions
Thrombotic Risk: Patients receiving Avatrombopag should be monitored for signs of excessive platelet production, which can increase the risk of thrombosis.
Hepatic Impairment: Caution is advised in patients with severe liver disease as dosage adjustments may be required.
Bleeding Risk: While Avatrombopag increases platelet count, it does not treat underlying causes of bleeding disorders; additional treatment may be necessary.
Pregnancy and Lactation: Use in pregnant or breastfeeding women should be considered only if the potential benefit justifies the risk.
Side Effects
Common adverse reactions associated with Avalet 20 mg include:
Headache
Fatigue
Nausea
Fever
Abdominal pain
Edema (swelling)
Insomnia
Thrombosis in rare cases
Serious side effects, though uncommon, may include blood clot formation, severe allergic reactions, or liver function abnormalities. Immediate medical attention is required if symptoms such as chest pain, shortness of breath, or unusual bruising occur.
Drug Interactions
Strong CYP3A4 inhibitors or inducers may alter the metabolism of Avatrombopag, requiring dose adjustments.
Anticoagulants and Antiplatelet Drugs: Concomitant use with blood thinners may require monitoring to balance the risk of clotting versus bleeding.
Iron Supplements: Iron and certain other minerals may affect Avatrombopag absorption; take them at least 4 hours apart.
Storage and Handling
Store at room temperature (15–30°C) away from direct sunlight and moisture.
Keep out of reach of children.
Do not use beyond the expiration date indicated on the packaging.
Conclusion
Avalet 20 mg (Avatrombopag) is an effective thrombopoietin receptor agonist that helps increase platelet counts in patients with chronic liver disease or chronic immune thrombocytopenia. It provides an oral, convenient alternative to platelet transfusions or other treatments, reducing the risk of bleeding complications in at-risk patients. However, careful monitoring and adherence to dosage guidelines are essential to ensure safety and efficacy. Patients should consult their healthcare provider for personalized treatment plans and regular follow-ups while on Avalet therapy.